FitLife Brands, Inc. 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023, compared with fiscal year 2022. The filing is an annual report, not a standalone fourth-quarter report. Dollar amounts are in thousands unless otherwise stated.
Business Context
FitLife develops, markets and distributes nutritional supplements and wellness products under NDS, iSatori, MRC and MusclePharm brands. Products are sold through GNC franchise and corporate stores, more than 17,000 specialty, mass-market and online locations, Amazon and other e-commerce platforms, company websites, and wholesale partners. The company operates as one reportable segment and is headquartered in Omaha, Nebraska.
- MRC was acquired on February 28, 2023 for $17,099, funded with $12,500 of term debt and $4,599 of cash.
- Substantially all MusclePharm assets were acquired on October 10, 2023 for $18,788, including legal costs; $10,000 was debt-financed and the remainder was funded with cash.
- FitLife had 37 full-time employees at December 31, 2023, compared with 27 at December 31, 2022.
Key Financial Metrics
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $52,700 | $28,803 | +83% |
| Gross profit | $21,432 | $12,034 | +78% |
| Gross margin | 40.7% | 41.8% | Down 1.1 points |
| Income from operations | $7,550 | $5,701 | +32% |
| Net income | $5,296 | $4,429 | +20% |
| Diluted earnings per share | $1.08 | $0.89 | +21% |
| Adjusted EBITDA | $10,179 | $6,705 | +52% |
| Cash flow from operations | $4,220 | $4,130 | +2% |
Online revenue represented approximately 63% of total revenue in 2023, compared with approximately 28% in 2022. Legacy FitLife revenue was $28,100, down 3%, as a 9% decline in wholesale revenue exceeded a 14% increase in online revenue. MRC contributed $24,370 of revenue and $1,975 of net income from acquisition through year-end. MusclePharm had minimal 2023 revenue impact because it was acquired late in the fourth quarter and required inventory procurement and customer-contract negotiations.
Cost of goods sold increased 86% to $31,268. Management attributed the margin decline primarily to $323 of MRC inventory fair-value step-up amortization and inflation-related product-cost increases. Excluding the step-up amortization, reported gross margin would have been approximately 41.3%.
Cash Flow, Liquidity and Debt
- Cash and cash equivalents declined to $1,139 at December 31, 2023 from $13,277, while restricted cash was $759.
- Positive working capital was $4,356, down from $18,933, primarily because of the two acquisitions and related cash funding.
- Operating cash flow was $4,220. Investing cash outflow was $35,993, consisting primarily of the MRC and MusclePharm acquisitions. Financing cash inflow was $20,296.
- Term-loan borrowings were $20,125 at year-end, consisting of $10,625 of Term Loan A and $9,500 of Term Loan B, with an effective stated interest rate of 8.21% at year-end. The balance sheet presented $4,500 as current and $15,509 as long-term debt net of deferred financing costs.
- The $3,500 revolving line of credit had no outstanding borrowings at year-end and was extended to December 15, 2024.
- The company was in compliance with its debt covenants at December 31, 2023 and stated that operating cash flow, existing cash and available revolver capacity are expected to fund the next twelve months.
- After year-end, FitLife made a scheduled $1,100 term-loan payment and a voluntary $2,500 payment on Term Loan A.
Material Changes Versus 2022
- Revenue and earnings increased substantially, primarily from the MRC acquisition and increased online sales, but the reported gross margin contracted.
- The business mix shifted toward online channels, while GNC represented 33% of 2023 revenue versus 67% in 2022.
- Acquisition-related expenses increased to $1,627 from $257. Management identified approximately $2.1 million of non-recurring items associated with the MRC transaction.
- SG&A increased 102% to $12,161, primarily reflecting MRC-related operating expenses.
- Assets increased to $55,346 from $25,707, principally due to acquired brands, goodwill and other intangible assets. Intangibles were $26,309 and goodwill was $13,294 at year-end.
- Debt increased from zero reported term-loan debt at year-end 2022 to $20,125 at year-end 2023, while liquidity decreased materially after acquisition spending.
- The company introduced 18 products in 2023, compared with 10 in 2022.
Guidance, Outlook, Risks and Unusual Items
Management did not provide formal revenue or earnings guidance. Management expects online revenue to continue increasing relative to prior periods and believes e-commerce development, MRC and MusclePharm can support future growth, but expressly provides no assurance.
- Key risks include dependence on GNC, Amazon and other distribution partners; GNC accounted for 33% of revenue and 30% of accounts receivable at year-end.
- The company relies on a limited number of third-party manufacturers and suppliers. One vendor represented 51% of accounts payable at year-end, and three vendors represented 37%, 30% and 10% of 2023 inventory-related purchases.
- Inflation, uncertain economic conditions, consumer demand, competition, product recalls, product liability, regulatory requirements and supply-chain interruptions could adversely affect results.
- Integration of MRC and MusclePharm may require significant management resources and may not produce expected revenue growth or synergies.
- Product returns and sales incentives liability was $571 at year-end; inventory obsolescence allowance was $162.
- No goodwill or long-lived-asset impairment charges were recorded in 2023. The substantial acquired intangible and goodwill balances remain sensitive to operating performance and valuation assumptions.
- The company reported no material pending litigation and no material cybersecurity incident identified as of the filing date.
- Management concluded that disclosure controls and internal control over financial reporting were effective at December 31, 2023 after implementing a remediation plan for previously reported material weaknesses. The external auditor did not provide an internal-control attestation because FitLife qualifies as a smaller reporting company.
- FitLife has never paid cash dividends and does not anticipate paying them in the foreseeable future. A $5,000 share-repurchase authorization remained available, but no shares were repurchased in 2023.
Most Important Facts to Verify
- Whether MRC and MusclePharm produce the expected revenue, cash flow and synergies after full-period integration.
- Whether cash generation is sufficient to fund scheduled debt amortization, including the $4,500 annual principal maturities shown for 2024 through 2027.
- Compliance with the 1.25-to-1.00 fixed-charge coverage covenant and the 2.50-to-1.00 funded-debt-to-EBITDA covenant as future testing periods begin.
- The sustainability of the shift to online revenue and the effect of e-commerce distribution fees on gross margins.
- Exposure to GNC, Amazon, concentrated suppliers, product returns, regulatory enforcement and product-liability claims.
- The valuation and impairment sensitivity of $26,309 of intangible assets and $13,294 of goodwill, including the assumptions underlying the MRC purchase-price allocation.
- The company’s ability to maintain positive operating cash flow given year-end cash of $1,139 and substantially higher leverage.